New Therapeutic Targets in Idiopathic Pulmonary Fibrosis: Aiming to Rein in Runaway Wound Healing Responses

Author: Neil Ahluwalia, Barry S. Shea, and Andrew M. Tager
Date Published: August-2014
Source: American Journal of Respiratory & Critical Care Medicine

Abstract - Idiopathic pulmonary fibrosis (IPF) is a devastating disease, with a median survival as short as 3 years from the time of diagnosis, and no pharmacological therapies yet approved by the US Food and Drug Administration (FDA). To address the great unmet need for effective IPF therapy, a number of new drugs have recently been, or are now being, evaluated in clinical trials. The rationales for most of these therapeutic candidates are based on the current paradigm of IPF pathogenesis, in which recurrent injury to the alveolar epithelium is thought to drive aberrant wound healing responses, resulting in fibrosis rather than repair.